1. Home
  2. LIDR vs RLYB Comparison

LIDR vs RLYB Comparison

Compare LIDR & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AEye Inc.

LIDR

AEye Inc.

HOLD

Current Price

$1.80

Market Cap

69.8M

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$16.08

Market Cap

75.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIDR
RLYB
Founded
2013
2018
Country
United States
United States
Employees
45
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.8M
75.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LIDR
RLYB
Price
$1.80
$16.08
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.75
N/A
AVG Volume (30 Days)
1.3M
78.5K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$858,000.00
Revenue This Year
$2,604.29
N/A
Revenue Next Year
$466.58
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.00
52 Week Low
$0.75
$0.30
52 Week High
$6.44
$17.57

Technical Indicators

Market Signals
Indicator
LIDR
RLYB
Relative Strength Index (RSI) 42.22 67.12
Support Level $1.74 $0.56
Resistance Level $2.81 N/A
Average True Range (ATR) 0.11 0.74
MACD -0.02 -0.06
Stochastic Oscillator 9.43 59.09

Price Performance

Historical Comparison
LIDR
RLYB

About LIDR AEye Inc.

AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: